Authorisation marks major step in European preparedness against ricin
News
Oxford Drug Design reports major in vivo milestone for novel cancer therapy
Data shows potential route to overcoming resistance in aggressive colorectal tumours
Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
Partnership will analyse m6A RNA modifications in patient samples to support development of STC‑15
Excellence adventure
The first Excellence in Healthcare Partnerships (EHP) Awards and Networking Evening is afoot
MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
New biologic option shown to reduce exacerbations and extend time to first flare
Bial launches new sublingual Parkinson’s treatment in UK
Sublingual apomorphine film offers rapid relief for OFF episodes
Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
First‑in‑class SK ion channel inhibitor enters next stage of clinical development
Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
Company aims to expand treatment options for relapsed or refractory multiple myeloma
HUTCHMED begins phase 3 stage of pancreatic cancer trial
Combination therapy moves into late‑stage testing after encouraging earlier results
Zenas reports strong phase 3 results for obexelimab in IgG4-related disease
Company prepares regulatory filings after treatment shows significant reduction in disease flare risk
MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
MRM’s platform could optimise the link between the gut microbiome and cancer outcomes
Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
Arthrosi’s investigational gout treatment is currently being evaluated in global studies
Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
The two companies aim to reduce administrative burden and speed up drug delivery
Title21 Health Solutions joins the Blood and Cells Advocacy Roster
The blood industry plays a vital role in supporting the development of advanced therapies
NADMED launches $30,000 metabolomics research award
Winners will receive metabolomics kits, expert consultation and measurement services
